The cytokine scatter factor/hepatocyte growth factor (HGF/SF) protects epithelial, carcinoma, and other cell types against cytotoxicity and apoptosis induced by DNAdamaging agents such as ionizing radiation and adriamycin (ADR, a topoisomerase IIa inhibitor). We investigated the role of nuclear factor kappa B (NF-jB) signaling in HGF/SF-mediated protection of human prostate cancer (DU-145) and Madin-Darby canine kidney (MDCK) epithelial cells against ADR. HGF/SF caused the rapid nuclear translocation of the p65 (RelA) subunit of NF-jB associated with the transient loss of the inhibitory subunit IjB-a. Exposure to HGF/SF caused the activation of an NF-jB luciferase reporter that was blocked or attenuated by the expression of a mutant 'super-repressor' IjB-a. Electrophoretic mobility shift assay supershift assays revealed that HGF/SF treatment induced the transient binding of various NF-jB family proteins (p65, p50, c-Rel, and RelB) with radiolabeled NF-jB-binding oligonucleotides. The HGF/SF-mediated protection of DU-145 and MDCK cells against ADR (demonstrated using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays) was abrogated by the IjB-a super-repressor. The ability of HGF/SF to activate NFjB signaling was dependent on c-Akt-Pak1 (p21-associated kinase-1) signaling (with Pak1 downstream of c-Akt) and was inhibited by the tumor suppressor PTEN (phosphatase and tensin homolog). Inhibitors of phosphatidylinositol-3 0 -kinase and Src family kinases significantly inhibited HGF/SF-mediated activation of NF-jB, while inhibitors of MEK, protein kinase C, and p70 S6 kinase had a modest effect or no effect on NF-jB activity. HGF/ SF induced the expression of several known NF-jB target genes (cIAP-1 (cellular inhibitor of apoptosis-1), cIAP-2, and TRAF-2 (TNF receptor-associated factor-2)) in an NF-jB-dependent manner; HGF/SF blocked the inhibition of expression of these genes by ADR. Experimental manipulation of expression of these genes suggests that they (particularly TRAF-2 and cIAP-2) contribute to the protection against ADR by HGF/SF. These findings
Introduction
The cytokine/growth factor hepatocyte growth factor/ scatter factor (HGF/SF) can modulate cell motility, proliferation, morphogenesis, angiogenesis, and tumorigenesis in different cell types and contexts. HGF/SF is a positive regulator of cell survival, based on its ability to block apoptotic signaling and/or activate antiapoptotic pathways (Frisch and Francis, 1994; Bardelli et al., 1996) . Thus, HGF/SF blocked apoptosis of MadinDarby canine kidney (MDCK) epithelial cells caused by detachment from the substratum (a phenomenon called 'anoikis') (Frisch and Francis, 1994) , suggesting that it can overcome the loss of an integrin-linked survival signal. A constitutively active, oncogenic form of the c-Met tyrosine kinase, the HGF/SF receptor (Bottaro et al., 1991) , blocked apoptosis and allowed immortalization of cultured hepatocytes (Amicone et al., 1997) . Although these and other studies indicate that HGF/SF is usually cytoprotective, proapoptotic effects were in hepatocarcinoma cells, due, in part, to a deficiency of hypoxia-inducible factor-1 (Matteucci et al., 2003) .
Recently, we reported that HGF/SF protects epithelial, carcinoma, and glioma cell lines against cytotoxicity and apoptosis induced by DNA-damaging agents (e.g. ionizing radiation and various chemotherapy drugs, including the DNA topoisomerase IIa inhibitor adriamycin (ADR, also known as doxorubicin)) (Fan et al., 1998 Bowers et al., 2000) . We also found that HGF/SF stimulates the repair of single-and double-stranded DNA breaks . The cell protection required the c-Met receptor and a prolonged preincubation with SF (X48 h for maximal effect), suggesting that it involved HGF/SF-regulated gene expression and new protein synthesis. One implication of these findings is that HGF/SF, which accumulates within various tumor types (e.g. breast cancers, gliomas, bladder cancers) (Jin et al., 1997; Rosen et al., 1998) , may render these tumors more resistant to radiation and chemotherapy, by blocking DNA damage-induced apoptosis and stimulating DNA repair.
The molecular mechanism(s) of HGF/SF-mediated cell protection has been the subject of several recent studies. In breast cancer (MDA-MB-453), glioma, and MDCK cell lines, protection by HGF/SF protection pathway involves signaling through phosphatidylinositol-3 0 -kinase (PI3K) and activation of the cell survivalpromoting serine/threonine kinase c-Akt (protein kinase B) (Bowers et al., 2000; Fan et al., 2000 Fan et al., , 2001 . Thus, inhibition of the enzymatic activities of PI3K or c-Akt significantly attenuated the ability of HGF/SF to protect these cell line types against DNA-damaging agents and to stimulate the repair of DNA strand breaks. In further studies of MDCK cells, we found that the multisubstrate adapter Gab1 (Grb2-associated binder-1) and the tumor suppressor PTEN (phosphatase and tensin homolog) act upstream of c-Akt to inhibit HGF/SF-mediated cell protection . In contrast, p21
Ras and Pak1 (the p21-associated kinase-1) (which acts downstream of c-Akt in some signaling pathways) function to regulate positively HGF/SFmediated cell protection .
The transcription factor nuclear factor kappa B (NFkB) is activated by a variety of signals, including inflammatory cytokines, growth factors, oxidative stress, and carcinogens. In response to a suitable signal, the cytoplasmic inhibitor IkB-a is phosphorylated (by the inhibitor of NF-kB kinase complex (IKKabg)) and undergoes ubiquitin-mediated degradation, allowing nuclear translocation of the NF-kB dimer (p65-p50) and transactivation of genes containing NF-kB response elements (Tan et al., 1999; Magnani et al., 2000) . NF-kB activation usually results in antiapoptotic signaling and cell protection, although NF-kB can promote apoptosis in certain contexts (Magnani et al., 2000; DeMeester et al., 2001) . Interestingly, NF-kB appears to function downstream of Ras, PI3K, and c-Akt in the protection of cells against apoptosis (Ozes et al., 1999) . Thus, we sought to determine if NF-kB signaling participates in the HGF/SF-mediated cell protection pathway.
Results

HGF/SF induces nuclear translocation of the p65 subunit of NF-kB
In response to a suitable stimulus (e.g. a proinflammatory cytokine such as tumor necrosis factor-a (TNF-a)), the cytoplasmic inhibitor IkB-a is rapidly phosphorylated on serine, causing dissociation from the NF-kB heterodimer (p65-p50), which can then undergo nuclear translocation and activate transcription (Tan et al., 1999; Magnani et al., 2000) . To determine if HGF/SF can activate NF-kB signaling, subconfluent DU-145 human prostate cancer cells were incubated with 100 ng/ ml of recombinant human HGF/SF for different time intervals and then subjected to immunofluorescence staining for the p65 subunit of NF-kB. Sham-treated control cells (T ¼ 0) showed little or no nuclear localization of p65, which exhibited a cytoplasmic localization (Figure 1a) . p65 was detected in the nucleus after 5 min, with an increased quantity of nuclear p65 observed after 10 min. At T ¼ 30 and 240 min (4 h), nearly all of the p65 staining was again cytoplasmic, indicating that the HGF/SF-induced nuclear accumulation of p65 was transient. Similarly, HGF/SF-induced nuclear accumulation of p65 was observed in MDCK epithelial cells (Figure 1b) .
To determine if the HGF/SF-induced relocalization of p65 is dependent on IkB-a, the ability of HGF/SF to cause nuclear localization of p65 was compared in MDCK cells expressing the mutant nonphosphorylatable and nondegradable IkB-a under the control of a Tet-Off promoter system vs vector control-transfected cells. The mutant IkB-a (S(32,36)A) binds but does not release NF-kB, thus acting as a 'super-repressor' of NF-kB signaling (Brockman et al., 1995) . As shown in Figure 1b , at T ¼ 30 min after the addition of HGF/SF, nearly all of the p65 immunostaining in the control became nuclear, whereas p65 immunostaining remained predominantly cytoplasmic in the mutant IkB-a cells. Figure 1c shows the induction of the IkB-a mutant (super-repressor) protein upon removal of doxycycline from the medium.
Typically, phosphorylation of IkB-a leads to its proteolysis via a ubiquitin-26S proteasomal degradation pathway, followed later by synthesis and reaccumulation in the cytoplasm (Tan et al., 1999; Magnani et al., 2000) . In HGF/SF-treated DU-145 cells, Western blotting revealed a loss of IkB-a by 30 min, followed by reaccumulation at T ¼ 240 min and 24 h (Figure 2 ). It was noted that the levels of IkB-a protein appeared to be increased transiently at T ¼ 240 min. Taken together, these findings suggest that the HGF/SF-mediated nuclear translocation of p65 involves phosphorylation and degradation of IkB-a.
HGF/SF stimulates NF-kB-dependent transcriptional activity
To determine if HGF/SF stimulates NF-kB activity, cells were transfected with an NF-kB-Luc reporter plasmid prior to treatment with HGF/SF. The NF-kB reporter contains five NF-kB-binding elements upstream of the luciferase gene. Reporter-transfected DU-145 cells showed a large HGF/SF-induced increase as compared with control-treated cells at T ¼ 24 h after addition of HGF/SF (Figure 3a) . Consistent with the transient induction of nuclear localization of NF-kB, DU-145 cells treated with HGF/SF for 30 min, then washed, postincubated in HGF/SF-free medium, and assayed at T ¼ 24 h showed NF-kB-Luc activity that was almost as high as that in cells exposed to HGF/SF continuously for 24 h. The ability of HGF/SF to induce NF-kB-Luc activity was greatly attenuated in DU-145 cells that had been cotransfected with the mutant nonphosphorylatable IkB-a at the same time as the NF-kB reporter (Po0.001, two-tailed t-test) (Figure 3a ). In agreement with these findings, HGF/SF induced a large increase in NF-kB-Luc activity in vector control but not IkB-a mutant expressing MDCK cell lines Subconfluent proliferating cells were incubated with HGF/SF (100 ng/ml) for the indicated times, and the localization of the p65 subunit of NF-kB was visualized by immunofluorescence microscopy. (b) Lack of nuclear accumulation of p65 in MDCK cells expressing mutant IkB-a. A vector control clone (T24) and a clone stably expressing an IkB-a mutant (super-repressor) vector under the control of a tetracycline-responsive (Tet-Off) were treated without or with HGF/SF (100 ng/ml) for 30 min and then assayed for p65 immunofluorescence. The IkB-a mutant were cultured in the absence of doxycycline for T ¼ 24 h prior to treatment with HGF/SF. (c) Tetracycline-regulated expression of mutant IkB-a in MDCK-IkB cells. The MDCK-IkB mutant (S32,36A) Tet-Off cell line was created as described in the Materials and methods section. These cells were routinely cultured in medium containing doxycycline (20 ng/ml) ( þ ) to suppress IkB expression. Culture in doxycycline-free medium for 24 h resulted in expression of the mutant IkB-a protein, as demonstrated by Western blotting using an anti-IkB-a antibody NF-jB signaling in HGF/SF-mediated cell protection S Fan et al ( Figure 3b ). These findings suggest that HGF/SF induces the IkB-a-dependent transcriptional activation of endogenous NF-kB.
Induction of transient DNA binding by different NF-kB family members in HGF/SF-treated cells
We used EMSA (electrophoretic mobility shift assay) supershift assays to assess the binding of different NF-kB family proteins in DU-145 nuclear extracts to radiolabeled oligonucleotides corresponding to the NF-kB response element. Briefly, subconfluent proliferating DU-145 cells were treated with HGF/SF (100 ng/ml) for different times, after which nuclear extracts were prepared, incubated with 32 P-labeled NFkB-specific oligonucleotides, and then incubated with antibodies against four different members of the NF-kB gene family: p65 ( ¼ RelA), RelB, c-Rel, and p50. These different NF-kB family proteins are illustrated schematically in Figure 4a . The supershift assay with anti-p65 revealed clear supershifts corresponding to 5 and 10 min but not at 30 min or later time points (see Figure 4b) , consistent with the previously described immunostaining data for DU-145 cells (Figure 1a) . We also found a supershift mostly at 5 and 10 min using anti-p50 and anti-c-Rel, with a much smaller (or no) quantity of shifted band at 30 min and later times. For RelB, we found evidence of a small amount of supershift at 10 min, and little or no shift band at later time points. These findings suggest that HGF/SF causes nuclear localization and DNA binding of multiple NF-kB family proteins.
Role of NF-kB signaling in HGF/SF-mediated cell protection
Previously, we showed that in various cell types (including DU-145, MDCK, MDA-MB-453, and glioma cells), preincubation with HGF/SF blocked cytotoxicity (measured using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay) and apoptosis (measured using DNA agarose gel electrophoresis, TUNEL, mitochondrial depolarization, and caspase activation assays) induced by ADR (a DNA topoisomerase IIa inhibitor) (Fan et al., 1998 Gao et al., 2001) . Here, we used the MTT assay of cell viability to compare cell survival in vector control vs IkB-a mutant MDCK cell lines. The MTT assay measures the ability of intact mitochondria to reduce a tetrazolium dye to formazan (Alley et al., 1988) . Briefly, subconfluent proliferating cells were preincubated7HGF/SF (100 ng/ml Â 48 h), treated with ADR (for 2 h at 371C), and postincubated in ADR-free medium for 48 h, prior to assay for MTT dye reduction. In the control cell line, pretreatment with HGF/SF nearly fully blocked the loss of cell viability caused by ADR (Po0.001 two-tailed t-test), whereas in the IkB-a mutant cell line, there was no difference in the viability of cells treated with ADR alone vs (HGF/ SF þ ADR) (see Figure 5a ). The survival of control cells treated with ADR alone was only slightly higher than that of IkB-a mutant cells treated with ADR alone (50 vs 40%, respectively).
We also tested the requirement for endogenous NFkB activity for HGF/SF-mediated protection against ADR in DU-145 cells. These assays were performed as described above, except that the cells were transiently transfected with the IkB-a mutant (super-repressor) expression vector (vs empty vector) prior to exposure to HGF/SF and ADR. Again, HGF/SF strongly protected the cells against ADR-induced cytotoxicity (Po0.001, two-tailed t-test), while the degree of cytoprotection was significantly attenuated by the IkB-a mutant (Po0.001) (see Figure 5b ). These findings suggest that NF-kB functional activity is required for the HGF/SF-mediated protection against ADR in both MDCK and DU-145 cells.
HGF/SF-mediated activation of NF-kB requires c-Akt and Pak1 and is inhibited by PTEN Next, we investigated the mechanism by which HGF/SF activates NF-kB signaling, using the NF-kB-Luc reporter as a readout of NF-kB activity. NF-kB reporter assays were performed in both DU-145 and MDCK cells ( Figure 6 ). In these experiments, NF-kB-Luc activity was expressed relative to the basal activity observed in the absence of any SF or transfected expression vectors. These studies revealed that in both cell types, a dominant-negative (kinase-defective) Akt (DN-Akt) ( Figure 6a ) and a DN-Pak1 (Figure 6b ) severely attenuated the HGF/SF-induced NF-kB-Luc activity. In the presence of DN-Akt or DN-Pak1, the reductions in fold activation by HGF/SF went from (40-50)-fold down to (2-3)-fold (Po0.001, two-tailed t-tests). We also found that in the absence of HGF/SF, DN-Akt ( Figure 6a ) and DN-Pak1 (Figure 6b ) caused a modest reduction in the basal NF-kB-Luc activity. Wild-type c-Akt (wtAkt), its activated (myristolated) counterpart (Akt-myr), and wild-type Pak1 (wtPak1) caused a significant stimulation of NF-kB activity in the absence of HGF/SF, although not as much as did HGF/ SF alone. The combination of the wild-type or activated Akt and Pak1 expression vectors plus HGF/SF gave significantly more stimulation of NF-kB-Luc activity than did either treatment alone (Po0.001).
Next, we tested the effect of exogenous PTEN (mutated in multiple advanced cancers-1), a phosphati- for different time intervals, after which the cells were harvested, nuclear extracts were prepared, and EMSA gel supershift assays were performed (see Materials and methods section). Panel a shows schematic diagrams of the four NF-kB family proteins studied in these experiments. The precursor protein p105 is cleaved at amino acid 433, releasing p50. GRR ¼ glycine-rich region; LZ ¼ leucine zipper; RHD ¼ Rel homology domain; and TAD ¼ transcriptional activation domain. Adapted from Hayden and Ghosh (2004) . Panels b-e represent supershift assays utilizing anti-p65, anti-RelB, anti-c-Rel, and anti-p50 antibodies. The upper arrow represents the supershifted band corresponding to the complex containing 32 P-labeled NFkB oligonucleotide plus NF-kB protein and anti-NF-kB antibody NF-jB signaling in HGF/SF-mediated cell protection S Fan et al dylinositol-3,4,5-trisphosphate 3 phosphatase that acts upstream of c-Akt and inhibits its activation (Wu et al., 1998) , on the ability of HGF/SF to stimulate NF-kB activity. Here, we found that wild-type PTEN (wtPTEN) significantly inhibited both the basal and HGF/SF-stimulated NF-kB-Luc activity (Po0.001), while a mutant PTEN (mut-PTEN) defective in the lipid phosphatase activity failed to inhibit or modestly stimulated NF-kB-Luc activity ( Figure 6c ). These findings implicate a c-Akt/Pak1-dependent pathway in HGF/SF-mediated activation of NF-kB.
Finally, we performed additional studies to determine the relative positions of c-Akt and Pak1 in HGF/SFinducible NF-kB activation by the use of a combination of wild-type and dominant-negative expression vectors for these proteins. As shown in Figure 6d , wtAkt and wtPak1 each enhanced the HGF/SF-induced NF-kBLuc activity, while each vector (DN-Akt or DN-Pak1) by itself nearly abrogated the ability of HGF/SF to upregulate NF-kB activity. The NF-kB-Luc activity in the presence of (HGF/SF þ DN-Akt þ wtPak1) was very similar to that in the presence of only (HGF/ SF þ wtPak1). However, the combination of (HGF/ SF þ wtAkt þ DN-Pak1) gave close to the baseline NF-kB activity, suggesting that Pak1 is downstream of c-Akt in the pathway of NF-kB activation by HGF/SF.
Role of other signal transduction pathways in HGF/SFmediated activation of NF-kB
To further delineate the pathway of NF-kB activation by HGF/SF, we tested a set of selective inhibitors of different signaling proteins to determine which can block HGF/SF-stimulated NF-kB-Luc activity in DU-145 and MDCK cells (Figures 7 and 8 ). Pharmacologic inhibitors tested included: GF109302X (a protein kinase C inhibitor); rapamycin (a p70 S6 kinase (Rsk-2) inhibitor); PD98059 (a mitogen-activated protein kinase kinase (MAPKK, or MEK) inhibitor); Wortmannin and LY294002 (PI3K inhibitors); and PP1 (4-amino-5-(4-methylphenyl)-7-(-t-butyl)pyrazolo-D-3,4-pyrimidine) (which inhibits Src family kinases). All agents were tested at doses proven effective in published studies and/ or at slightly higher doses. We also tested expression vectors, including DN-MEK (a dominant-negative MAPKK (or MEK)]; wild-type and dominant-negative (DN) forms of Cdc42; an activated form of Rac1 (RacV12); a DN-Rac1 (RacN17); wild-type Rho; a DN-Rho (RhoN17); wild-type Src; and a DN-Src.
NF-kB-Luc activity was expressed as a percent of the positive control (i.e. in the presence of HGF/SF alone). The pharmacologic inhibitors GF109302X, rapamycin, and PD98059 yielded either modest or no inhibition of HGF/SF-stimulated NF-kB-Luc activity (o25% reduction in activity) in both DU-145 and MDCK cells at all doses tested (Figures 7a-c) . Similarly, the DN-MEK expression vector caused only a modest reduction of HGF/SF-stimulated NF-kB-Luc activity (about 15%) ( Figure 7d ). In contrast, the two inhibitors of PI3K (Wortmannin and LY294002) caused a significant dosedependent inhibition of HGF/SF-stimulated NF-kBLuc activity in both DU-145 and MDCK cells (Figures 7e and f, respectively). The magnitude of the reductions in activity ranged from 70 to 95%.
We also tested the effect of several small GTPases (Cdc42, Rac1, and Rho) on HGF/SF-induced NF-kB- MDCK vector control and IkB-a mutant (super-repressor) cell clones were preincubated 7 HGF/SF (100 ng/ml) for 48 h, treated with ADR (15 mM Â 2 h), washed, and postincubated for 48 h, after which the cell viability was determined using the MTT assay. Values of cell viability are expressed relative to untreated control cells and are means7s.e.m.'s of N ¼ 10 replicate wells. Note that for both MDCK and DU-145, cell viability was significantly higher in cells treated with (HGF/SF þ ADR) as compared with ADR alone (Po0.001, two tailed t-test). However, the IkB mutant significantly reduced (or abrogated) the protection against ADR by HGF/SF (Po0.001, two-tailed t-test)
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Luc activity in DU-145 and MDCK cells. We found that wild-type Cdc42 enhanced HGF/SF-induced NF-kBLuc activity (by about 50-70%), while DN-Cdc42 reduced this activity (by about 30-40%) (Figure 7g ). Wild-type Rho enhanced HGF/SF-induced NF-kB-Luc activity (by 1.7-2.2-fold), while DN-Rho reduced the activity by about 50% in DU-145 cells and had no effect on the activity in MDCK cells (Figure 7h ). Finally, an activated form of Rac1 (RacV12) increased HGF/SFinduced NF-kB-Luc activity (by about 2.8-fold), while a DN-Rac1 (RacN17) reduced the activity (by about 20-50%) in the two cell types (Figure 7i ). These findings suggest that small GTPases may play some role in HGF/SF-induced NF-kB-Luc activity, probably more so in DU-145 than MDCK cells. In contrast to the modest effects of the signal transduction inhibitors GF109302X, rapamycin, and PD98059, the Src family kinase inhibitor PP1 caused a strong dose-dependent inhibition of HGF/SF-stimulated NF-kB-Luc activity, with inhibition rates of 75-90% at doses of 25-30 mM of PP1 in DU-145 and MDCK cells (Figure 8a ). To determine if cytotoxicity might contribute to some of this reduction of NF-kB activity, we performed parallel MTT assays using DU-145 cells (Figure 8b ). The PP1-induced loss of MTT signal was much smaller in magnitude than the inhibition of NF-kB activity: 2% at 10 mM of PP1 (which gave 50% inhibition of HGF/SF-stimulated NF-kB-Luc activity) and 10-20% at 25-30 mM of PP1 (which gave 75-90% inhibition). We also found that the ability of wild-type Akt (wtAKT) to enhance HGF/SF-stimulated NF-kB-Luc activity was strongly inhibited by PP1; PP1 blocked the ability of Akt to stimulate NF-kB-Luc activity in the absence of HGF/SF (Figure 8c ). To confirm a role for Src in HGF/SF stimulation of NF-kB activity, we performed similar experiments in cells transfected with a wild-type Src, a DN-Src, or empty vector. In the absence of HGF/SF, Src caused a small increase in NF-kB-Luc activity; however, Src enhanced the HGF/SF-stimulated NF-kB-Luc activity by 4.4-4.6-fold (Figure 8d ). Importantly, DN-Src strongly inhibited the HGF/SF-stimulated NF-kB-Luc activity, while the empty vector had no effect on NF-kB activity. These findings suggest that Src contributes to the HGF/SF-inducible NF-kB activity; their significance is considered further in the Discussion. In panels a-c, wtAkt, Akt-myr, and wtPak1 significantly increased, while DN-Akt, DN-Pak1, and wtPTEN significantly inhibited, the HGF/SF-stimulated NF-kB-Luc activity (Po0.001, two-tailed t-tests). In panel d, the combination of (wtAkt þ DN-Pak1) but not (DN-Akt þ wtPak1) inhibited HGF/SF-stimulated NFkB-Luc activity (Po0.001) NF-jB signaling in HGF/SF-mediated cell protection S Fan et al
HGF/SF induces expression of NF-kB target genes
Since HGF/SF stimulated the activity of an NF-kB-Luc reporter, we tested its ability to induce expression of several known NF-kB target genes: cIAP-1 (cellular inhibitor of apoptosis-1), cIAP-2, and TRAF-2 (TNF receptor-associated factor-2) Micheau et al., 2001) . Studies were performed using DU-145 and U373MG cells. The latter is a human glioblastoma cell line that is protected against DNAdamaging agents by HGF/SF (Bowers et al., 2000) . U373MG cells were used for these studies because the PCR primers and antibodies corresponded to the human rather than canine (MDCK) protein. The cells were treated with HGF/SF for 48 h and then analysed for gene expression, using rigorously controlled semiquantitative RT-PCR analyses. At this time, mRNA levels of cIAP-1, cIAP-2, and TRAF-2 were all increased in the HGF/SF-treated cells; in contrast, expression of the control gene (b-actin) was unchanged (Figure 9a ). In agreement with the RT-PCR assays, Western blotting revealed that the protein levels of cIAP-1, cIAP-2, and TRAF-2 were also increased (Figure 9a ). Similar to In panels e and f, Wortmannin and LY294002 each caused a significant dose-dependent reduction of HGF/SF-stimulated NFkB-Luc activity (Po0.001, two-tailed ttests). In panels g-i, Cdc42, Rho, and RacV12 significantly enhanced HGF/SF-stimulated NFkB-Luc activity (Po0.001). DN-Cdc42 inhibited HGF/SF-stimulated NFkB-Luc activity for both DU-145 and MDCK cells, while RhoN17 and RacN17 inhibited this activity for DU-145 but not MDCK cells (Po0.001-0.01) NF-jB signaling in HGF/SF-mediated cell protection S Fan et al DU-145 cells, HGF/SF also stimulated the mRNA expression of the three NF-kB target genes in U373MG cells (Figure 9b ). To determine if the HGF/SF induced increase in cIAP-1, cIAP-2, and TRAF-2 gene expression was dependent on the activation of NF-kB, cells were transfected overnight with empty vector (control) or IkB-a mutant (super-repressor), and then treated with HGF/SF for 48 h. For both DU-145 ( Figure 9c ) and U373MG (Figure 9d ) cells, expression of the IkB-a mutant abrogated the HGF/SF-induced increases in the mRNA levels of cIAP-1, cIAP-2, and TRAF-2. Previously, we showed that pretreatment with HGF/ SF for 48 h protects DU-145 and other cell types against cytotoxicity and apoptosis induced by ADR (Fan et al., 1998 . To determine if the induction of these three NF-kB target genes might contribute to the protection of DU-145 cells against ADR, the cells were preincubated7HGF/SF, then treated7ADR, postincubated for 48 h in fresh ADR-free medium, and assayed for gene expression. Semi-quantitative RT-PCR assays revealed that HGF/SF alone stimulated and ADR alone inhibited the expression of cIAP-1, cIAP-2, and TRAF-2. However, pre-incubation with HGF/SF attenuated the inhibition of gene expression caused by ADR (Figure 10a) . Here, b 2 -microglobulin was used as the control gene rather than b-actin, because the levels of b-actin are sometimes altered (decreased) by ADR. These results correlated with similar changes observed at the protein level, although in some cases (e.g. TRAF-2), the protein bands were relatively weak (Figure 10b ).
Role of NF-kB target genes in HGF/SF-mediated cell protection
The above studies suggest but do not prove that TRAF-2, cIAP-1, and cIAP-2 might contribute to NF-jB signaling in HGF/SF-mediated cell protection S Fan et al HGF/SF-mediated cell protection against ADR. We performed further studies to determine if these HGF/ SF-induced NF-kB target genes are required for or contribute to HGF/SF protection against ADR. Two approaches were taken: one approach was to determine if enforced expression of the gene could protect DU-145 cells against ADR in the absence of HGF/SF, and the other was to determine if inactivation of the gene using a small interfering RNA (siRNA) could abrogate or attenuate the HGF/SF-mediated protection. For each gene (TRAF-2, cIAP-1, and cIAP-2), we created an active siRNA and a control siRNA. (The sequences of these siRNAs, concentrations used, and the transfection conditions are described in the Materials and methods section.) Before using them, we confirmed that each active siRNA (but not the control siRNAs) downregulated expression of the gene of interest without causing cytotoxicity (as determined using MTT assays). Subconfluent proliferating DU-145 cells were preincubated 7 HGF/SF (100 ng/ml) for 48 h, after which the total cell RNA was extracted and subjected to rigorously controlled semi-quantitative RT-PCR analysis to detect cIAP-1, cIAP-2, TRAF-2, and b-actin (control for loading). Each PCR reaction was individually optimized for the gene of interest, and all PCR reactions were carried out within the linear range of product amplification. In parallel cultures, cells treated 7 HGF/SF for 48 h were harvest for protein analyses, and whole-cell extracts were subjected to Western blotting to detect cIAP-1, cIAP-2, TRAF-2, and a-actin (control for loading and transfer). Subconfluent proliferating cells were transfected overnight with a wild-type expression vector or empty vector, washed, incubated7HGF/SF (100 ng/ml Â 48 h), exposed to different doses of ADR (for 2 h at 371C), and postincubated for 48 h. Alternatively, the cells were pretreated with the active or control-siRNA (100 nM Â 48 h), incubated7HGF/SF (100 ng/ml Â 48 h), exposed to different doses of ADR as above, and postincubated for 48 h. The cells were analysed for cell viability using the MTT assay. Cell viability values were expressed relative to non-ADR-treated control cells. Figure 11a shows the effect of TRAF-2 on dosedependent cytotoxicity caused by ADR. As compared with untransfected or empty vector-transfected cells, wild-type TRAF-2-transfected cells showed 15-30% increases in cell viability depending on the dose of ADR (Figure 11a, left panel) . On the other hand, while HGF/SF (with or without empty vector) significantly protected the cells against ADR, there was no additional protection conferred by (HGF/SF þ TRAF-2) ( Figure  11a , second from left panel). Next, we found that TRAF-2-siRNA had little or no effect on ADR-induced cytotoxocity, but TRAF-2-siRNA (but not controlsiRNA) abrogated the HGF/SF-mediated protection against ADR (Figure 11a, two right panels) .
In Figure 11b , we tested the contribution of cIAP-1 to the survival of ADR-treated DU-145 cells. Exogenous cIAP-1 (but not empty vector) (in the absence of HGF/ SF) conferred a 10-15% increase in cell viability at different doses of ADR (Figure 11b, left panel) . The degree of cell protection was significantly higher in the presence of (HGF/SF þ cIAP-1) than in the presence of either agent alone (Figure 11b , second to left panel). A control-siRNA had little or no effect on cell viability in response to ADR (relative to cells treated with vehicle alone), while a cIAP-1-siRNA attenuated the survival of ADR-treated cells (Figure 11b , second to right panel). As was true for TRAF-2-siRNA, cIAP-1-siRNA (but not the control-siRNA) blocked or strongly attenuated the HGF/SF-mediated cell protection (Figure 11b , right panel). Figure 11c shows the effect of over-or underexpression of c-IAP-2 on survival of DU-145 cells in response to ADR7HGF/SF. These results were qualitatively similar to those observed for TRAF-2. Here, exogenous cIAP-2 caused a significant increase in survival in response to ADR and little or no change in the HGF/SF-mediated protection against ADR ( Figure  11c , two left panels). While cIAP-2-siRNA had little or no effect on the survival response to ADR, it nearly abrogated the HGF/SF-mediated protection against ADR (Figure 11c , two right panels). These findings suggest that all three genes, but particularly TRAF-2 and cIAP-2, may contribute to the HGF/SF-mediated protection of DU-145 cells against ADR.
Discussion
We showed that in several epithelial cell types (DU-145 prostate cancer and MDCK epithelial cells), HGF/SF causes nuclear translocation of the p65 subunit of the NF-kB heterodimer and stimulates NF-kB activity. These effects were blocked by the IkB-a super-repressor, which contains a mutation (S(32,36)A) that prevents phosphorylation of IkB-a but does not affect its binding to p65. The IkB-a super-repressor attenuated or abrogated the protection of MDCK and DU-145 cells by HGF/SF against cytotoxicity caused by ADR, a topoisomerase IIa inhibitor that causes DNA strand breaks. Furthermore, in studies of DU-145 and Subconfluent proliferating DU-145 cells were preincubated 7 HGF/SF (100 ng/ml Â 48 h), exposed to ADR (15 mM Â 2 h), and postincubated in fresh drug-free medium for another 48 h. The total cell RNA was extracted and subjected to rigorously controlled semi-quantitative RT-PCR analysis to detect cIAP-1, cIAP-2, TRAF-2, and b 2 -microblobulin (control for loading). Each PCR reaction was individually optimized for the gene of interest, and all PCR reactions were carried out within the linear range of product amplification. (b) Western blot analysis. Subconfluent proliferating DU-145 cells were preincubated 7 HGF/SF (100 ng/ml Â 48 h), exposed to ADR (15 mM Â 2 h), and postincubated in fresh drug-free medium for another 48 h. Wholecell lysates were prepared and subjected to Western blotting to detect cIAP-1, cIAP-2, TRAF-2, and b-tubulin (control for loading and transfer) NF-jB signaling in HGF/SF-mediated cell protection S Fan et al U373MG (glioblastoma) cells, HGF/SF induced the expression of three known NF-kB target genes (cIAP-1, cIAP-2, and TRAF-2), all of which have been implicated in protecting cells against apoptosis Micheau et al., 2001) . Expression of these NF-kB target genes was blocked by the IkB-a super-repressor, implicating NF-kB signaling in their induction by HGF/SF.
Several prior studies evaluated the effects of HGF/SF on NF-kB signaling, with mixed findings. Thus, HGF/ SF stimulated NF-kB signaling in a liver cell line (MLP29), and inhibition of NF-kB blocked HGF/ SF-induced proliferation and tubulogenesis, but not scattering (Muller et al., 2002) . However, NF-kB was not required for the antiapoptotic function of HGF/SF. NF-kB activation also occurred in rat hepatocytes, where functional cooperation of p65 and JunD was found (Rahmani et al., 2001) . HGF/SF activated NF-kB in HepG2 cells, and the activation was enhanced by the protein kinase C inhibitor H7 (Rahmani et al., 2001) . AGP/EBP (alpha-1-acid glycoprotein (CCAAT/enhancer binding protein-b)) was induced by HGF/SF, in part, through NF-kB activation (Shen et al., 1997) . The ability of HGF/SF to protect cells against anoikis (apoptosis caused by detachment from the underlying substrate) was described earlier (Frisch and Francis, Figure 11 Role of TRAF-2, cIAP-1, and cIAP-2 in HGF/SF-mediated protection against ADR. In panel a, subconfluent proliferating DU-145 cells were transfected overnight with a wild-type TRAF-2 expression vector or empty vector, washed, incubated 7 HGF/SF (100 ng/ml Â 48 h), exposed to different doses of ADR (for 2 h at 371C), and postincubated for 48 h. Alternatively, the cells were pretreated with TRAF-2-siRNA or control-siRNA (100 nM Â 48 h), incubated 7 HGF/SF (100 ng/ml Â 48 h), exposed to the indicated doses of ADR (for 2 h at 371C), and postincubated for 48 h. The cells were then analysed for cell viability using the MTT assay. Similar experiments were performed for cIAP-1 (panel b) and cIAP-2 (panel c). Cell viability values are expressed relative to non-ADR-treated control cells and represent means7s.e.m.'s of 10 replicate wells. Statistical comparisons: In panels a-c, exogenous TRAF-2, cIAP-1, and cIAP-2 by themselves (but not empty vector) conferred a significant degree of protection against ADR (Po0.001-0.01 at most doses of ADR, two-tailed t-tests). HGF/SF alone, in the presence of empty vector, or in the presence of control-siRNA significantly protected DU-145 cells at all doses of ADR tested (Po0.001-0.01). When combined with HGF/SF, TRAF-2 and cIAP-2 expression vectors gave a similar amount of protection against ADR as HGF/SF alone (P ¼ NS), while cIAP-1 gave additional protection (Po0.001-0.01 for all except the lowest dose of ADR). By themselves, TRAF-2-siRNA and cIAP-2-siRNA had no effect on the survival response to ADR (P ¼ NS), while cIAP-1-siRNA reduced survival to below that in the presence of control-siRNA or ADR alone (Po0.001-0.01). TRAF-2-siRNA, cIAP-1-siRNA, and cIAP-2-siRNA (but not the control siRNAs) significantly attenuated the HGF/SF-mediated protection at each dose of ADR (Po0.001-0.01) NF-jB signaling in HGF/SF-mediated cell protection S Fan et al 1994) . In a study of head and neck squamous carcinoma cells, it was found that HGF/SF protection against anoikis involved c-Akt and ERK but not NF-kB signaling (Zeng et al., 2002) . As noted earlier, HGF/ SF can cause apoptosis in some cell types (e.g. hepatoma) (Matteucci et al., 2003) . These findings suggest that the ability of HGF/SF to activate NF-kB and promote cell survival may be specific for the cell type and the apoptogenic stimulus. EMSA supershift assays revealed that HGF/SF induces the transient binding of multiple NF-kB family proteins (p65/RelA, RelB, p50, and c-Rel) to NF-kBbinding oligonucleotides in DU-145 cells, suggesting that more than one NF-kB dimer could contribute to HGF/SF-mediated cell protection. Consistent with the time-course immunofluorescence assays of HGF/SFinduced nuclear translocation of p65/RelA in DU-145 cells, supershifts were observed after 5-10 min of stimulation with HGF/SF, with little or no shifted bands seen at 30 min, 4 h, or 24 h. Thus, the rapid nuclear translocation and transient DNA binding of NF-kB family proteins is sufficient to mediate protection against ADR.
NF-kB is downstream of the serine/threonine kinase c-Akt in signaling pathways activated by several cytokines and growth factors (e.g. TNF-a and plateletderived growth factor) (Ozes et al., 1999; Romashkova and Makarov, 1999; Bell et al., 2003) . These pathways involve PI3K-dependent activation of c-Akt and c-Aktmediated phosphorylation and activation of an IkB kinase (IKK-a) (Ozes et al., 1999; Romashkova and Makarov, 1999; Bell et al., 2003) . The IKK complex phosphorylates IkB-a, which dissociates from the p65-p50 heterodimer, allowing nuclear translocation of NFkB. The p65 subunit of NF-kB can also be activated by phosphorylation, which can occur through PI3K/c-Aktdependent and -independent mechanisms, in different contexts (Sizemore et al., 2002; Yang et al., 2003) .
The cytotoxicity assays establish that NF-kB signaling is required for protection against ADR, since protection of DU-145 and MDCK cells was blocked by the IkB-a super-repressor. Previously, we showed that Ras, PI3K, and c-Akt are required for the protection of MDCK, carcinoma, and glioma cell lines against ADR by HGF/SF (Bowers et al., 2000; Fan et al., 2000 Fan et al., , 2001 , and the tumor suppressor PTEN, which inhibits c-Akt signaling, blocked HGF/SF protection against ADR . Here, we found that c-Akt is required for and PTEN inhibits NF-kB activation by HGF/SF. The inhibition of NF-kB activation by PTEN presumably occurred via inhibition of c-Akt activation, due to dephosphorylation of phosphatidylinositol-3,4,5-trisphosphate (which is required for c-Akt membrane localization and activation). A mutant phosphatase-defective PTEN failed to inhibit NF-kB activation.
We also reported that p21-associated kinase (Pak1) is required for the protection of MDCK cells against ADR . Here, we found that Pak1 is required for the activation of NF-kB by HGF/SF, and that Pak1 is downstream of c-Akt in this pathway. Activated Pak1 can associate with the NF-kB-inducing kinase (Nik) and activate the IKK complex, which phosphorylates IkB-a (Foryst-Ludwig and Naumann, 2000) . It was also shown that NF-kB activation by several stimuli requires Pak1, and that expression of activated Pak1 induces p65 nuclear translocation independent of IKK-a or IKK-b (Frost et al., 2000) . Taken together, these findings suggest that NF-kB is downstream of c-Akt-Pak1 signaling in the pathway of HGF/SF protection against genotoxic stress in the cell types that we studied.
We also assessed the roles of other signal transduction pathways in HGF/SF activation of NF-kB, using selective inhibitors of these pathways. Consistent with the requirement of Akt for NF-kB activity, two inhibitors of PI3K -which is needed for c-Akt activation -strongly attenuated HGF/SF-stimulated NF-kB activity. Various studies suggest that MEK-ERK signaling can positively or negatively regulate NF-kB activity, depending on the cell type and context (Janssen-Heininger et al., 1999; Carter and Hunninghake, 2000; Kurland et al., 2003; Jiang et al., 2004) . However, inhibitors of MEK, protein kinase C, and p70 S6 kinase caused a modest inhibition (0-25%) of NF-kB activation. In contrast, an Src inhibitor (PP1) strongly inhibited HGF/SF-stimulated NF-kB activity. Exogenous Src simulated, while a DN-Src expression vector nearly abrogated, NF-kB activation by HGF/SF. Several studies suggest a role for Src in NF-kB activation (Liu et al., 2001; Fan et al., 2003; Saijo et al., 2003; Davis et al., 2004) . The mechanism(s) of activation of NF-kB by Src (a tyrosine kinase) is not entirely clear but may involve activation of IKK or tyrosine phosphorylation of IkB. Src kinases may also act as upstream activators of c-Akt (Hakak et al., 2000; Windham et al., 2002) . The ability of PP1 to inhibit HGF/SF, Akt, and (HGF/SF þ Akt)-induced NF-kB activity suggests that it may inhibit an Src kinase downstream of c-Akt, but our studies do not rule out a role of Src upstream of c-Akt in the activation of NF-kB.
Interestingly, a combination of HGF/SF plus exogenous Akt, Pak1, or Src stimulated NF-kB activity by (2.5-3.5)-fold more than HGF/SF alone. However, by themselves, Akt, Pak1, and Src each stimulated NF-kBLuc activity to a significantly lesser extent than HGF/ SF. A likely explanation for the lesser efficacy of the exogenous genes in stimulating NF-kB-Luc activity by themselves is that the overexpressed signaling proteins are incompletely activated in the absence of HGF/SF. cMet receptor signaling induced by HGF/SF presumably allows greater activation of the overexpressed signaling proteins, leading to higher NF-kB-Luc activity. Alternatively, or in addition, HGF/SF activates additional pathways needed for maximal NF-kB activity. In this model, activation of Akt, Pak1, and Src is required for HGF/SF induction of NF-kB activity (consistent with the loss of induction by DN inhibitors), but another HGF/SF-activated pathway(s) is required to maximally stimulate NF-kB activity.
We also found that HGF/SF induces the NF-kBmediated expression of cIAP-1, cIAP-2, and TRAF-2, and inhibits the ADR-induced downregulation of these genes. These three proteins have been shown to cooperate to inhibit TNF-a and etoposide-induced apoptosis . Etoposide causes genotoxicity through a similar mechanism to that of ADR (i.e. the inhibition of topoisomerase IIa, leading to doublestranded breaks of DNA), raising the possibility that these proteins may similarly contribute to protection against ADR by HGF/SF, which requires NF-kB activity. It was shown that TRAF-2 associates with the TNF-a receptor either directly or through the adapter protein TRADD (TNF receptor-associated death domain protein) (Park et al., 2000) . The TRADD-TRAF-2 interaction appears to be required for inhibition of apoptosis and recruitment of cIAPs to the death receptor complex.
We found that exogenous cIAP-1, cIAP-2, and TRAF-2 each protected DU-145 cells against ADR in the absence of HGF/SF (although the protection was sometimes modest), while knockdown of each protein by RNA interference abrogated or greatly reduced the degree of protection against ADR by HGF/SF. These findings suggest a role for these three genes as intermediaries for HGF/SF-mediated protection against ADR. One caveat is that for cIAP-1 (but not the other two genes), (HGF/SF þ cIAP-1) gave more protection than HGF/SF alone, and cells treated with (cIAP-1-siRNA þ ADR) showed lower survival than cells treated with ADR alone. Thus, cIAP-1 can yield effects on survival beyond those caused by (HGF/SF þ ADR) or ADR alone. None of the exogenous cDNAs by themselves (cIAP-1, cIAP-2, or TRAF-2) protected the cells as much as did HGF/SF. This finding probably reflects the fact that HGF/SF induces multiple target genes that contribute independently to cell protection.
Although TRAF-2 couples to a number of proteins, the mechanism by which it promotes cell survival is not well defined. TRAF-2 is a component of the TNF-a receptor signaling complex that mediates antiapoptotic signaling, in part, via NF-kB (Kawamata et al., 1998a, b) , but it is not required for NF-kB activation and it transduces NF-kB-independent survival pathways that act along with NF-kB to counteract proapoptotic signaling due to TNF-a and other stimuli (Lee et al., , 1998 . One TRAF-2 stimulated survival pathway involves sphingolipid signaling. TRAF-2 interacts with sphingosine kinase and enhances its ability to convert sphingosine into sphingosine-1-phosphate, an antiapoptotic sphingolipid (Xia et al., 2002) . Sphingosine kinase activation may be required for activation of NF-kB by TRAF-2 (Xia et al., 2002) , but sphingosine-1-phosphate may also inhibit apoptosis independently of NF-kB. TRAF-2 also participates in an antiapoptotic pathway involving the caspase-8 inhibitor c-FLIP (FLICE-like inhibitory protein), a downstream target of NF-kB (Micheau et al., 2001) . Thus, c-FLIP recruits RIP (death domain containing receptor interacting protein) and TRAFs-1 and -2, leading to the activation of ERK and NF-kB (Gupta, 2003) . Studies of TRAF-2 À/À embryonic fibroblasts suggest that TRAF-2 is required to prevent proteolytic degradation of c-FLIP, and that exogenous c-FLIP rescues the increased sensitivity to TNF-ainduced apoptosis (Guiet et al., 2002) . Most studies on TRAF-2 have examined its function in response to signaling from death receptors. Our findings suggest a role for TRAF-2 in ADR-induced toxicity and its prevention by HGF/SF.
The extent to which death receptors participate in ADR-induced cytotoxicity and protection by HGF/SF is unclear. We found that in human breast cancer cells (MDA-MB-453), ADR activates both mitochondrial (cytochrome c, caspases-9, -3, and -7) and death receptor (Fas/Fas ligand) apoptosis pathways, and both pathways are blocked by HGF/SF . The mitochondrial pathway was activated earlier (24 h or less) than the death receptor pathway (48-72 h) and is probably the more important pathway for ADR-induced cytotoxicity. HGF/SF inhibited ADRinduced upstream apoptosis signaling events (e.g. mitochondrial depolarization and release of cytochrome c and apoptosis-inducing factor) . The pancaspase inhibitor z-VAD-fmk also (partially) reversed ADR-induced cytotoxicity, suggesting that postmitochondrial events may contribute independently to the cytotoxicity. The present study suggests that inhibition of the downstream caspases by IAPs may contribute to the protection against ADR by HGF/SF. However, our findings do not exclude the possibility that IAPs also, or instead, act to inhibit upstream proapoptotic events.
Materials and methods
Sources of reagents
Recombinant human HGF/SF was generously provided by Dr Ralph Schwall, Department of Endocrine Research, Genentech, Inc. (South San Francisco, CA, USA). ADR (doxorubicin hydrochloride) and MTT dye (thioazyl blue) were purchased from Sigma Chemical Co. (St Louis, MO, USA). The primary antibodies used for Western blotting are described below under Western blot analysis. The sources of signal transduction inhibitors were as follows: Wortmannin (BioMol Research Laboratories (Plymouth Meeting, PA, USA)), LY294002 (Sigma), PD98059 (Biomol), GF109302X (LC Laboratories (Woburn, MA, USA)), rapamycin (Biomol), and PP1 (Biomol). All drugs were dissolved in dimethyl sulfoxide (DMSO), and diluted into culture medium at the time of experiments.
Cell culture DU-145 human prostate, MDCK epithelial, and U373MG human glioblastoma cells were originally obtained from the American Type Culture Collection (Manassas, VA, USA). The cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with fetal calf serum (10% (v/v)), nonessential amino acids (100 mM), L-glutamine (5 mM), streptomycin (100 mg/ml), and penicillin (100 U/ml) (all from BioWhittaker, Walkersville, MD, USA). The transfected MDCK cell lines are described below. All cell lines were grown at 371C in a humidified atmosphere of 95% air and 5% CO 2 .
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Expression vectors and cell transfections
The pCMV4-IkB-a mutant (S32,36A) expression vector has been described earlier (Brockman et al., 1995) . This vector encodes a nonphosphorylatable and nondegradable mutant IkB-a in which serines 32 and 36 are mutated to alanines. IkBa S32,36A acts as a 'super-active' IkB-a and a 'super-repressor' of NF-kB transcriptional activity. For transient transfections, subconfluent proliferating cells were transfected overnight using Lipofectamine (Life Technologies) (15 mg of plasmid DNA per 100-mm dish) and then washed to remove the excess vector and Lipofectamine. Vectrs encoding wtAkt, a dominant-negative (DN) kinase inactive (K179A) mutant Akt (DN-Akt), and a membranetargeted (myristolated) Akt (Akt-myr) (all within the pCIS2 expression vector) were provided by Dr Michael Quon (National Heart, Lung, and Blood Institute, Bethesda, MD, USA) (Cong et al., 1997) . The wild-type (wtPTEN) and mutant (phosphatase-defective) (mut-PTEN) expression vectors were provided by Dr MM Georgescu (Rockefeller University, New York, NY, USA) (Georgescu et al., 1999) . Expression vectors encoding wild-type (wtPak1) and kinase dead (K299R) dominant-negative (DN-Pak1) p21-associated kinase have been described earlier (Adam et al., 2000) . These Pak1 vectors were provided by Dr R Kumar (University of Texas MD Anderson Cancer Center, Houston, TX, USA).
The following plasmids were provided by Richard G Pestell (Lombardi Comprehensive Cancer Center, Georgetown University): DN-MEK (which encodes a dominant-negative mitogen-activated protein kinase kinase (MAPKK)) (Peyssonnaux et al., 2000) ; Rho (encoding wild-type RhoA); RhoN19 (encoding a DN-Rho protein, in the pcDNA vector); Cdc42 (encoding wild-type Cdc42, in the pcDNA3 vector); Cdc42N17 (encoding a DN-Cdc42 protein); RacV12 (encoding a constitutively active Rac1 protein, in the pEF vector); RacN17 (encoding a DN-Rac1 protein); Src (encoding a wild-type c-Src protein, in the pSGT vector); and SrcDSH3 (encoding a DN-Src). The Rho, Cdc42, and Rac1 expression vectors have been described earlier (Bouzahzah et al., 2001) . The Src and DN-Src vectors were also described earlier (Ostareck-Lederer et al., 2002) . Expression vectors for cIAP-1 and cIAP-2 were kindly provided by Dr John C. Reed (Burnham Institute, La Jolla, CA, USA) (Deveraux et al., 1998) . The TRAF-2 expression vector was provided by Dr Ze'ev Ronai (Ruttenberg Cancer Center, Mount Sinai School of Medicine, New York, NY, USA) (Habelhah et al., 2002) . Note that the substitution of an asparagine ( ¼ N) residue for the amino acid at position 17 of small GTPases Cdc42 and Rac1 (position 19 for Rho) reduces their affinity for GTP, thus creating dominant-negative mutants (Egan and Weinberg, 1993) .
MDCK-IkB cell lines
The MDCK-IkB-a mutant (S32,36A) cell line was created as follows. The IkB super-repressor insert was cloned out of the pCMV4 vector using HindIII and SmaI and ligated into the pTRE2 Tet-Off vector (Clonetech) to make it Tet-inducible (by removing tetracycline). Stable inducible MDCK cell lines were made by transfecting this construct with a 10-fold molar excess of a zeocin resistance plasmid (pCMV-ZEO, Invitrogen) into the MDCK T23 parental Tet-Off cell line. Clonal populations were selected in medium containing 500 mg/ml Zeocin (Invitrogen) and analysed by Western blotting using a rabbit polyclonal anti-IkB-a antibody (UBI). These cell lines were cultured in DMEM with 10% fetal calf serum in the presence of doxycycline (20 ng/ml). To induce expression of IkB-a S32,36A, doxycycline was removed from the medium at least 24 h before an experiment.
Reporter assays
The NF-kB-Luc reporter plasmid (pNF-kB-Luc) was purchased from Stratagene (La Jolla, CA, USA). This reporter is made up of five copies of the NF-kB enhancer element (Ron et al., 1990) upstream of a TATA box and the luciferase gene. Subconfluent proliferating cells in 24-well dishes were transfected overnight with 0.25 mg of each indicated vector (NF-kBLuc reporter7various expression vectors) using Lipofectamine. The cells were washed to remove Lipofectamine and excess vectors, treated7HGF/SF (100 ng/ml) for the indicated time interval, and harvested for measurement of luciferase activity. In some experiments, the cells were coincubated with 7HGF/SF (100 ng/ml) and 7 a pharmacologic inhibitor of signal transduction (see above) for T ¼ 24 h, and then harvested for luciferase assays. The relative transfection efficiency was determined using the Galacto-Star Mammalian Reporter Gene Assay System (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's protocol . Luciferase assays were performed using the Dual Luciferase Reporter Assay System (Promega, Piscataway, NJ, USA). Luciferase values were means7s.e.m.'s of quadruplicate wells. Each experiment was performed at least twice to assure the reproducibility of the findings.
ADR treatment
Subconfluent proliferating cells in 100-mm plastic dishes or 96-well plates were preincubated without or with HGF/SF (100 ng/ml for 48 h) in serum-free DMEM and then shamtreated (control) or treated with ADR (15 mM for 2 h at 371C) in complete culture medium. Cultures were then washed twice to remove the ADR and postincubated in fresh, drug-free complete culture medium at 371C for up to 48 h. Cells were harvested at different time points as indicated in the figure legends (usually T ¼ 48 h) for Western blot analysis, semiquantitative RT-PCR assays, or MTT assays of cell viability (see below).
MTT cell viability assay
This assay is based on the ability of viable mitochondria to convert MTT, a soluble tetrazolium salt, into an insoluble formazan precipitate, which is dissolved in DMSO and quantitated by spectrophotometry (Alley et al., 1988) . Cells were seeded into 96-well dishes (2000 cells/well) in standard growth medium, incubated for 24-48 h to allow attachment and entry into the cell cycle, preincubated 7 HGF/SF (100 ng/ ml Â 48 h), treated with ADR for 2 h, postincubated for 48 h, and tested for MTT dye conversion. Cell viability was calculated as the amount of MTT dye conversion relative to sham-treated control cells.
EMSA supershift assays
Subconfluent proliferating DU-145 cells were treated with HGF/SF (100 ng/ml) for different times (0-24 h); nuclear extracts were prepared by a modified Dignam protocol (Andrews and Faller, 1991) . Cells in 60-mm dishes were washed twice and scraped into ice-cold phosphate-buffered saline (PBS) containing 1 mM phenylmethylsulfonyl fluoride (PMSF). The cells were pelleted in microfuge tubes and resuspended in 400 ml of ice-cold low-salt buffer A (10 mM HEPES, pH 7.9, 1.5 mM MgCl 2 , 10 mM KCl). After 10 min on ice, 25 ml of 10% Nonidet P-40 was added. The samples were vortexed for 10 s, and then centrifuged (13 000 g) for 30 s at 41C; the pellet was resuspended in 30 ml of ice-cold high-salt buffer C (20 mM HEPES, pH 7.9, 25% glycerol, 420 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA). The resuspended pellets were allowed to rock gently at 41C for 30 min and then centrifuged at 41C for 15 min. The supernatant (nuclear extract) was saved and protein concentration was determined by the Bradford assay. Before using both buffers A and C, a fresh mixture of inhibitors was added to each to a final concentration of 1 mM PMSF, 1 mg/ml leupeptin A, 1 mM dithiothreitol (DTT), and 1 mM sodium orthovanadate.
The basic methodology for the supershift assays has been described earlier (Sica et al., 1997; Hellerbrand et al., 1998) . Double-stranded consensus oligonucleotides sequences representing the NF-kB response element (5 0 -AGT TGA GGG GAC TTT CCC AGG C-3 0 and 3 0 -TCA ACT CCC CTG AAA GGG TCC G-5 0 ) were purchased from Promega (Madison, WI, USA). To prepare gel shift probes, oligonucleotides were labeled with [g-32 P]ATP (Amersham, Piscataway, NJ, USA) using the T4 polynucleotide kinase, by the protocol provided (Gel Shift Assay System, Promega, Piscataway, NJ, USA). Unincorporated nucleotides were removed by Centri-Sep spin columns (Princeton Separations, Adelphia, NJ, USA). The 32 P-labeled oligonucleotides combined with 3 mg of nuclear extract in 20 ml of reaction buffer (50 mM TrisHCl, pH 7.5, 5 mM EDTA, 2.5 mM DTT, 250 mM NaCl, 0.25 mg/ml poly-dI-dC (Amersham, Piscataway, NJ, USA)). 'Supershifting' was conducted by then incubating the samples with different NF-kB family antibodies (6 mg/sample) for 45 min at room temperature. Supershift polyclonal antibodies against synthetic peptides from the NF-kB/Rel family of proteins p65 (RelA), p50, c-Rel (p75), and RelB (p68) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The reaction products were subjected to electrophoresis at 200 V at 41C for approximately 90 min on 5.5% nondenaturing polyacrylamide gels in high ionic strength TGE buffer (50 mM Tris-HCl, 380 mM glycine, 2 mM EDTA, pH 8.5). Lanes with samples were devoid of any loading dyes, which interfere with the binding reactions. Dried gels were exposed to Storm Phosphor Imaging plates (Molecular Dynamics, Sunnyvale, CA, USA) and viewed by IMAGE-QUANT software (Molecular Dynamics, Sunnyvale, CA, USA).
Small interfering RNAs
Custom SMARTpool plus siRNAs to target human cIAP-1, cIAP-2, and TRAF-2 were designed and synthesized by Dharmacon Inc. (Lafayette, CO, USA). These sequences on which these siRNAs were based are as follows: TRAF2-siRNA, 5 0 -GGA GTG TCC TGC ATG TAA A-3 0 and TRAF-2 scrambled-sequence control-siRNA, 5 0 -AGT ACG TTG CCG TGG AAT A-3 0 ; c-IAP-1-siRNA, 5 0 -ACA GAC GTC TTT ACA AGC A-3 0 and cIAP-1 scrambled-sequence control siRNA, 5 0 -CCA ATA GTA GTA CCC AAG T-3 0 ; and c-IAP-2-siRNA, 5 0 -ATA GCA CGA TCT TGT CAG A-3 0 and cIAP-2 scrambled-sequence control siRNA, 5 0 -CAC AGG TAA CAT AGT CGT T-3 0 . siRNA (50 nM) was transfected into DU-145 cells using Oligofectamine (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Cells were preincubated with siRNAs for 48 h, by which time the active (but not control) siRNAs caused a significant reduction of protein levels, as determined by Western blotting.
Semi-quantitative RT-PCR analysis
Rigorously controlled semi-quantitative RT-PCR analysis was performed as described earlier by us Yuan et al., 2001) . Briefly, the total cellular RNA was extracted using TRIzol Reagent (Life Technologies Inc.) according to the manufacturer's instructions. The RNA was treated with DNase and precipitated using 95% ethanol prior to cDNA synthesis. Isolated RNA was electrophoresed through 1.0% agarose-formaldehyde gels to verify the quality of the RNA; the concentrations of RNA were determined from absorbance measurements at 260 nm. Aliquots of total cellular RNA (5.0 mg) were subjected to first-strand cDNA synthesis using Superscript II reverse transcriptase (Life Technologies Inc.), and the cDNA was diluted 10 times with water. A measure of 1 ml of the diluted cDNA was used for each PCR reaction.
The PCR amplifications were performed using a PerkinElmer DNA thermal cycler. The PCR primer sets used in this study are shown in Table 1 . All PCR reaction conditions were individually optimized for each gene product studied. For each gene product, the cycle number was adjusted so that the reactions fell within the linear range of product amplification (Table 1 ). The b-actin and b 2 -microglobulin genes were used as controls for loading. PCR products were analysed by electrophoresis through 1.0% agarose gels containing 0.1 mg/ ml of ethidium bromide, and the gels were photographed under ultraviolet illumination.
Confocal laser scanning microscopy
Cells were seeded at 1 Â 10 5 /well in an eight-well Lab-Tek chamber chamber slide (Nunc, Naperville, IL, USA) in 0.5 ml of culture medium. The cells were fixed for 1 h in room temperature with freshly prepared 3.7% formaldehyde fixation solution in phosphate buffer. The fixation was followed by two After immunocytochemical staining, the cells were examined with an Olympus 1 Â 70 confocal laser fluorescence inverted microscope with objective lenses ( Â 40) (Olympus, Japan) using a laser with an excitation wavelength of 488 nm for FITC. The images were collected through the specimens every 2 mm in the vertical plane and overlaid to generate focus composite images. The images were displayed on computer screen using Fluoview software.
Western blot analyses
Cells were collected using trypsin, washed twice with PBS, and then pelleted by centrifugation. The pellet was resuspended in RIPA buffer (1 Â PBS, 1% NP-40, 0.5% sodium desoxycholate, and 0.1% sodium dodecyl sulfate (SDS)), placed on ice for 30 min, and spun for 15 min at 14 000 r.p.m. at 41C to remove the insoluble material. Western blot analyses were performed essentially as described earlier (Fan et al., 1998 . Briefly, equal aliquots of whole-cell lysate protein (50 mg/lane) were electrophoresed through 4-20% SDS-polyacrylamide gradient gels and transferred to nitrocellulose membranes (Millipore). The membranes were blotted using the primary antibodies of interest: mouse anti-human cIAP-1 monoclonal (1 : 500 dilution; R&D Systems Inc., Minneapolis, MN, USA), rabbit anti-human cIAP-2 polyclonal (1 : 500 dilution; R&D Systems), mouse anti-human TRAF-2 monoclonal (1 : 500 dilution; Upstate Biotechnology, Lake Placid, NY, USA), goat anti-human a-actin polyclonal (1 : 1000 dilution; Santa Cruz), and mouse anti-human tubulin monoclonal (1 : 1000 dilution; Santa Cruz). The membranes were then blotted with the appropriate secondary antibodies (1 : 1000 dilution; Santa Cruz), and the blotted proteins were visualized using the enhanced chemiluminescence detection system (Amersham Pharmacia Biotech), with colored markers (Bio-Rad Laboratories, Hercules, CA, USA) as size standards.
Statistical analyses
Where appropriate, statistical comparisons were made using the two-tailed Student's t-test.
